In vitro activity and pharmacodynamic/pharmacokinetic parameters of clarithromycin and azithromycin: why they matter in the treatment of respiratory tract infections

References

• SoodSKMacrolides: clarithromycin and azithromycinSemin Pediatr Infect Dis19991012330
   Google Scholar
• PetersDHClissoldSPClarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potentialDrugs19924411171641379907
   PubMed Web of Science ®Google Scholar
• DinosGPThe macrolide antibiotic renaissanceBr J Pharmacol2017174182967298328664582
   PubMed Web of Science ®Google Scholar
• ShulmanSTBisnoALCleggHWClinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of AmericaClin Infect Dis201255101279128223091044
   PubMed Web of Science ®Google Scholar
• van DrielMLDe SutterAIHabrakenHThorningSChristiaensTDifferent antibiotic treatments for group A streptococcal pharyngitisCochrane Database Syst Rev20169CD00440627614728
   PubMed Web of Science ®Google Scholar
• ChiappiniERegoliMBonsignoriFAnalysis of different recommendations from international guidelines for the management of acute pharyngitis in adults and childrenClin Ther2011331485821397773
   PubMed Web of Science ®Google Scholar
• SelaSBarzilaiAWhy do we fail with penicillin in the treatment of group A Streptococcus infections?Ann Med199931530330710574501
   PubMed Web of Science ®Google Scholar
• SaviniVCatavitelloCTaliaMBeta-lactam failure in treatment of two group G Streptococcus dysgalactiae subsp. equisimilis pharyngitis patientsJ Clin Microbiol200846281481618057124
   PubMed Web of Science ®Google Scholar
• GoochWM3rdGanVNCorderWTKhuranaCMAndrewsWPClarithromycin and cefaclor suspensions in the treatment of acute otitis media in childrenPediatr Infect Dis J19931212 Suppl 3S128S1338295814
   PubMed Web of Science ®Google Scholar
• AspinMMHobermanAMcCartyJComparative study of the safety and efficacy of clarithromycin and amoxicillin-clavulanate in the treatment of acute otitis media in childrenJ Pediatr199412511361418021763
   PubMed Web of Science ®Google Scholar
• McCartyJMPhillipsAWiisanenRComparative safety and efficacy of clarithromycin and amoxicillin/clavulanate in the treatment of acute otitis media in childrenPediatr Infect Dis J19931212 Suppl 3S122S1278295813
   PubMed Web of Science ®Google Scholar
• ColesSJAddlestoneMBKamdarMKMacklinJLA comparative study of clarithromycin and amoxycillin suspensions in the treatment of pediatric patients with acute otitis mediaInfection19932142722788225637
   PubMed Web of Science ®Google Scholar
• AronovitzGA multicenter, open label trial of azithromycin vs. amoxicillin/clavulanate for the management of acute otitis media in childrenPediatr Infect Dis J1996159 Suppl1519
   Web of Science ®Google Scholar
• DaganRJohnsonCEMcLinnSBacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis mediaPediatr Infect Dis J20001929510410693993
   PubMed Web of Science ®Google Scholar
• Anti-infective Review PanelAnti-infective guidelines for community acquired infectionsToronto, ONMUMS Guideline Clearinghouse2013
   Google Scholar
• ForgieSZhanelGRobinsonJManagement of acute otitis mediaPaediatr Child Health200914745746420808476
   PubMed Web of Science ®Google Scholar
• LieberthalASCarrollAEChonmaitreeTThe diagnosis and management of acute otitis mediaPediatrics20131313e964e99923439909
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care ExcellenceGuideline: otitis media (acute): antimicrobial prescribing2017 Available from: https://www.nice.org.uk/guidance/gid-apg10001/documents/draft-guidelineAccessed July 11, 2018
   Google Scholar
• DuboisJSaint-PierreCTremblayCEfficacy of clarithromycin vs. amoxicillin/clavulanate in the treatment of acute maxillary sinusitisEar Nose Throat J199372128048108313865
   PubMedGoogle Scholar
• AdelglassJJonesTMRuoffGA multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitisPharmacotherapy1998186125512639855324
   PubMed Web of Science ®Google Scholar
• RifferESpillerJPalmerRShortridgeVBusmanTAValdesJOnce daily clarithromycin extended-release vs twice-daily amoxicillin/clavulanate in patients with acute bacterial sinusitis: a randomized, investigator-blinded studyCurr Med Res Opin2005211617015881476
   PubMed Web of Science ®Google Scholar
• CasianoRRAzithromycin and amoxicillin in the treatment of acute maxillary sinusitisAm J Med1991913A27S30S
   Web of Science ®Google Scholar
• Gutiérrez-CastrellónPMayorga-BuitronJLBosch-CantoVSolomon-SantibañezGde Colsa-RaneroAEfficacy and safety of clarithromycin in pediatric patients with upper respiratory infections: a systematic review with meta-analysisRev Invest Clin201264212613522991774
   PubMedGoogle Scholar
• AwCBenningerMSBrookIExecutive summary: IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adultsClin Infect Dis20125410411045
   Web of Science ®Google Scholar
• ScaddingGKDurhamSRMirakianRBSACI guidelines for the management of rhinosinusitis and nasal polyposisClin Exp Allergy200838226027518167126
   PubMed Web of Science ®Google Scholar
• OakleyGMHarveyRJLundVJThe role of macrolides in chronic rhinosinusitis (CRSsNP and CRSwNP)Curr Allergy Asthma Rep20171753028429305
   PubMed Web of Science ®Google Scholar
• BishaiWRMacrolide immunomodulatory effects and symptom resolution in acute exacerbation of chronic bronchitis and acute maxillary sinusitis: a focus on clarithromycinExpert Rev Anti Infect Ther20064340541616771618
   PubMedGoogle Scholar
• CervinAWallworkBMackay-SimAComanWBGreiffLEffects of long-term clarithromycin treatment on lavage-fluid markers of inflammation in chronic rhinosinusitisClin Physiol Funct Imaging200929213614219076731
   PubMed Web of Science ®Google Scholar
• BanerjeeDHoneybourneDKhairOAThe effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trialTreat Respir Med200431596515174894
   PubMedGoogle Scholar
• AndersonRSteelHCCockeranRClarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniaeJ Antimicrob Chemother200759222422917218449
   PubMed Web of Science ®Google Scholar
• ChienSMPichottaPSiepmanNChanCKTreatment of community-acquired pneumonia: a multi-center, double-blind, randomized study comparing clarithromycin with erythromycinChest199310336977018449054
   PubMed Web of Science ®Google Scholar
• AndersonGEsmondeTSColesSMacklinJCarnegieCA comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumoniaJ Antimicrob Chemother199127Suppl A117124
   PubMed Web of Science ®Google Scholar
• O’DohertyBMullerORandomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study GroupEur J Clin Microbiol Infect Dis1998171282883310052544
   PubMed Web of Science ®Google Scholar
• MacklinJLJamesIKearsleyNJColesSJA single-blind, randomised, comparative study of clarithromycin and amoxycillin suspensions in the treatment of children with lower respiratory tract infectionsJ Chemother1993531741808371127
   PubMed Web of Science ®Google Scholar
• GotfriedMHDattaniDRifferEA controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumoniaClin Ther200224573675112075942
   PubMed Web of Science ®Google Scholar
• SokolWNJrSullivanJGAcamporaMDBusmanTANotarioGFA prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumoniaClin Ther200224460561512017405
   PubMed Web of Science ®Google Scholar
• Querol-RibellesJMTeníasJMQuerol-BorrásJMLevofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalizationInt J Antimicrob Agents2005251758315620830
   PubMed Web of Science ®Google Scholar
• LinTYLinSMChenHCAn open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumoniaChang Gung Med J200730432133217939262
   PubMedGoogle Scholar
• HardyDJSwansonRNRodeRAMarshKShipkowitzNLClementJJEnhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humansAntimicrob Agents Chemother1990347140714132143642
   PubMed Web of Science ®Google Scholar
• PakhaleSMulpuruSVerheijTJKochenMMRohdeGGBjerreLMAntibiotics for community-acquired pneumonia in adult outpatientsCochrane Database Syst Rev201410CD002109
   Google Scholar
• SliglWIAsadiLEurichDTTjosvoldLMarrieTJMajumdarSRMacrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysisCrit Care Med201442242043224158175
   PubMed Web of Science ®Google Scholar
• MandellLAWunderinkRGAnzuetoAInfectious Diseases Society of America/American Thoracic Society consensus Guidelines on the management of community-acquired pneumonia in adultsClin Infect Dis200744Suppl 2S27S7217278083
   PubMed Web of Science ®Google Scholar
• LevyMLLe JeuneIWoodheadMAMacfarlaneJTLimWSBritish Thoracic Society Community Acquired Pneumonia in Adults Guideline GroupPrimary care summary of the British Thoracic Society Guidelines for the management of community acquired pneumonia in adults: 2009 update endorsed by the Royal College of General Practitioners and the Primary Care Respiratory Society UKPrim Care Respir J2010191212720157684
   PubMedGoogle Scholar
• BradleyJSByingtonCLShahSSExecutive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of AmericaClin Infect Dis201153761763021890766
   PubMed Web of Science ®Google Scholar
• HarrisMClarkJCooteNBritish Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011Thorax201166Suppl 2ii1ii2321903691
   PubMed Web of Science ®Google Scholar
• BradburyFComparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infectionJ Antimicrob Chemother199331Suppl E153162
   PubMed Web of Science ®Google Scholar
• SwansonRNLainez-VentosillaADe SalvoMCDunneMWAmsdenGWOnce-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomized studyTreat Respir Med20054313915725048
   PubMedGoogle Scholar
• SiemposIIDimopoulosGKorbilaIPMantaKFalagasMEMacrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysisEur Respir J20072961127113717301097
   PubMed Web of Science ®Google Scholar
• DonathEChaudhryAHernandez-AyaLFLitLA meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with chronic obstructive pulmonary diseaseRespir Med201310791385139223768735
   PubMed Web of Science ®Google Scholar
• WenzelRPFowlerAAEdmondMBAntibiotic prevention of acute exacerbations of COPDN Engl J Med2012367434034722830464
   PubMed Web of Science ®Google Scholar
• GotfriedMHDeAbateCAFogartyCMathewCPSokolWNComparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitisClin Ther20012319710711219483
   PubMed Web of Science ®Google Scholar
• WilsonRSchentagJJBallPMandellL068 Study GroupA comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomesClin Ther200224463965212017408
   PubMed Web of Science ®Google Scholar
• DunnCJBarradellLBAzithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infectionsDrugs19965134835058882383
   PubMed Web of Science ®Google Scholar
• FernandesPBBailerRSwansonRIn vitro and in vivo evaluation of A-56268 (TE-031), a new macrolideAntimicrob Agents Chemother19863068658732949695
   PubMed Web of Science ®Google Scholar
• HardyDJGuayDRJonesRNClarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overviewDiagn Microbiol Infect Dis199215139531530914
   PubMed Web of Science ®Google Scholar
• LangtryHDBrogdenRNClarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patientsDrugs199753697310049179528
   PubMed Web of Science ®Google Scholar
• RetsemaJGirardASchelklyWSpectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against Gram-negative organismsAntimicrob Agents Chemother19873112193919472449865
   PubMed Web of Science ®Google Scholar
• WhitmanMSTunkelARAzithromycin and clarithromycin: overview and comparison with erythromycinInfect Control Hosp Epidemiol19921363573681320067
   PubMed Web of Science ®Google Scholar
• EdnieLMVisalliMAJacobsMRAppelbaumPCComparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococciAntimicrob Agents Chemother1996408195019528843313
   PubMed Web of Science ®Google Scholar
• BarryALPfallerMAFuchsPCPackerRRIn vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993Antimicrob Agents Chemother19943810241924257840581
   PubMed Web of Science ®Google Scholar
• AppelbaumPCAntimicrobial resistance in Streptococcus pneumoniae: an overviewClin Infect Dis199215177831617076
   PubMed Web of Science ®Google Scholar
• KaysMBDenysGAIn vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokineticsClin Ther200123341342411318076
   PubMed Web of Science ®Google Scholar
• GotoHMulticenter surveillance of adult atypical pneumonia in Japan: its clinical features, and efficacy and safety of clarithromycinJ Infect Chemother20111719710421210175
   PubMed Web of Science ®Google Scholar
• HamedaniPAliJHafeezSThe safety and efficacy of clarithromycin in patients with Legionella pneumoniaChest19911006150315061835689
   PubMed Web of Science ®Google Scholar
• LozaEMartínez BeltránJBaqueroFComparative in vitro activity of clarithromycinEur J Clin Microbiol Infect Dis19921198568661468430
   PubMed Web of Science ®Google Scholar
• UnalDFenerciogluAOzbayLOzkirimBErolDThe effect of hydroxy metabolites of clarithromycin to the pharmacokinetic parameters, and determination of hydroxy metabolites ratio of clarithromycinEur J Drug Metab Pharmacokinet2009341273019462925
   PubMed Web of Science ®Google Scholar
• MartinSJGarvinCGMcBurneyCRSahloffEGThe activity of 14-hydroxy clarithromycin, alone and in combination with clarithromycin, against penicillin- and erythromycin-resistant Streptococcus pneumoniaeJ Antimicrob Chemother200147558158711328768
   PubMed Web of Science ®Google Scholar
• WalkerKJLarssonAJZabinskiRARotschaferJCEvaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic modelAntimicrob Agents Chemother1994389200320077811010
   PubMed Web of Science ®Google Scholar
• BergeronMGBernierML’EcuyerJIn vitro activity of clarithromycin and its 14-hydroxy-metabolite against 203 strains of Haemophilus influenzaeInfection19922031641671386590
   PubMed Web of Science ®Google Scholar
• HooverWWBarrettMSJonesRNClarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycinDiagn Microbiol Infect Dis19921532592661533827
   PubMed Web of Science ®Google Scholar
• BergmanKLOlsenKMPeddicordTEFeyPDRuppMEAntimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of Haemophilus influenzae and Streptococcus pneumoniaeAntimicrob Agents Chemother19994351291129310223956
   PubMed Web of Science ®Google Scholar
• EisenbergFBarzaMAzithromycin and clarithromycinCurr Clin Topics Infect Dis1994145279
   PubMedGoogle Scholar
• FouldsGShepardRMJohnsonRBThe pharmacokinetics of azithromycin in human serum and tissuesJ Antimicrob Chemother199025Suppl A7382
   PubMed Web of Science ®Google Scholar
• NeuHCThe development of macrolides: clarithromycin in perspectiveJ Antimicrob Chemother199127Suppl A19
   PubMed Web of Science ®Google Scholar
• PiscitelliSCDanzigerLHRodvoldKAClarithromycin and azithromycin: new macrolide antibioticsClin Pharm19921121371521312921
   PubMedGoogle Scholar
• GotfriedMHDanzigerLHRodvoldKASteady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjectsJ Antimicrob Chemother200352345045612888589
   PubMed Web of Science ®Google Scholar
• RodvoldKAGotfriedMHDanzigerLHServiRJIntrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteersAntimicrob Agents Chemother1997416139914029174209
   PubMed Web of Science ®Google Scholar
• PatelKBXuanDTessierPRRussomannoJHQuintilianiRNightingaleCHComparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycinAntimicrob Agents Chemother19964010237523798891147
   PubMed Web of Science ®Google Scholar
• NightingaleCHPharmacokinetics and pharmacodynamics of newer macrolidesPediatr Infect Dis J19971644384439109156
   PubMed Web of Science ®Google Scholar
• ConteJEJrGoldenJDuncanSMcKennaELinEZurlindenESingle-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjectsAntimicrob Agents Chemother1996407161716228807050
   PubMed Web of Science ®Google Scholar
• BaldwinDRWiseRAndrewsJMAshbyJPHoneybourneDAzithromycin concentrations at the sites of pulmonary infectionEur Respir J1990388868901963411
   PubMed Web of Science ®Google Scholar
• KastnerUGuggenbichlerJPInfluence of macrolide antibiotics on promotion of resistance in the oral flora of childrenInfection200129525125611688901
   PubMed Web of Science ®Google Scholar
• KikuchiEYamazakiKKikuchiJPharmacokinetics of clarithromycin in bronchial epithelial lining fluidRespirology200813222122618339019
   PubMed Web of Science ®Google Scholar
• GanVNMcCartyJMChuSYCarrRPenetration of clarithromycin into middle ear fluid of children with acute otitis mediaPediatr Infect Dis J199716139439002099
   PubMed Web of Science ®Google Scholar
• SundbergLCederbergAPenetration of clarithromycin and its 14-hydroxy metabolite into middle ear effusion in children with secretory otitis mediaJ Antimicrob Chemother19943322993078182011
   PubMed Web of Science ®Google Scholar
• PukanderJRautianenMPenetration of azithromycin into middle ear effusions in acute and secretory otitis media in childrenJ Antimicrob Chemother199637Suppl C5361
   PubMed Web of Science ®Google Scholar
• MargaritisVKIsmailosGSNaxakisSSMastronikolisNSGoumasPDSinus fluid penetration of oral clarithromycin and azithromycin in patients with acute rhinosinusitisAm J Rhinol200721557457817999793
   PubMedGoogle Scholar
• ZhanelGGDeCorbyMNoreddinAPharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrationsJ Antimicrob Chemother2003521838812775677
   PubMed Web of Science ®Google Scholar
• NoreddinAMRobertsDNicholKWierzbowskiAHobanDJZhanelGGPharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrationsAntimicrob Agents Chemother200246124029403412435719
   PubMed Web of Science ®Google Scholar
• DoernGVHeilmannKPHuynhHKRhombergPRCoffmanSLBrueggemannABAntimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995Antimicrob Agents Chemother20014561721172911353617
   PubMed Web of Science ®Google Scholar
• PowisJMcGeerAGreenKIn vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002Antimicrob Agents Chemother20044893305331115328089
   PubMed Web of Science ®Google Scholar
• LowDEResistance and treatment implications: pneumococcus, Staphylococcus aureus and Gram-negative rodsInfect Dis Clin North Am19983613630
   Web of Science ®Google Scholar
• HydeTBGayKStephensDSMacrolide resistance among invasive Streptococcus pneumoniae isolatesJAMA2001286151857186211597287
   PubMed Web of Science ®Google Scholar
• BergmanMHuikkoSHuovinenPPaakkariPSeppäläHFinnish Study Group for Antimicrobial Resistance (FiRE Network)Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniaeAntimicrob Agents Chemother2006503646365016940064
   PubMed Web of Science ®Google Scholar
• BlondeauJMShebelskiSDHesjeCKKilling of Streptococcus pneumoniae by azithromycin, clarithromycin, erythromycin, telithromycin and gemifloxacin using drug minimum inhibitory concentrations and mutant prevention concentrationsInt J Antimicrob Agents201545659459925752567
   PubMed Web of Science ®Google Scholar
• MetzlerKDrlicaKBlondeauJMMinimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniaeJ Antimicrob Chemother201368363163523169894
   PubMed Web of Science ®Google Scholar
• HoffmanHLKlepserMEErnstEJPetzoldCRSa’AdahLMDoernGVInfluence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection modelAntimicrob Agents Chemother200347273974612543686
   PubMed Web of Science ®Google Scholar
• DavidsonRJChanCCKDoernGZhanelGGMacrolide-resistant Streptococcus pneumoniae in Canada: correlation with azithromycin useClin Microb Infect20039240
   Google Scholar
• KusterSPRudnickWShigayevaAPrevious antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: results from prospective surveillanceClin Infect Dis201459794495224973312
   PubMed Web of Science ®Google Scholar